A recent study has identified a rare brain condition associated with the use of popular weight-loss medications including Ozempic, Wegovy, Mounjaro, and Zepbound. Wernicke encephalopathy, a neurological disorder caused by a significant deficiency of vitamin B1, also known as thiamine, has been reported in a small number of cases.
Read More
In total, researchers noted 15 cases from 2023 and 2024 involving individuals taking GLP-1 medications that contain semaglutide or tirzepatide. Vitamin B1 is crucial for maintaining proper nerve function, and its deficiency can lead to symptoms such as confusion, balance issues, and abnormal eye movements.
Untreated, Wernicke encephalopathy can result in permanent brain damage or even death, categorizing it as a medical emergency. The appetite-suppressing effects of GLP-1 drugs can lead to reduced food intake, particularly of vitamin B1-rich foods like pork, fish, and whole grains.
Many patients who developed the condition reported experiencing severe vomiting, loss of appetite, poor nutrition, or rapid weight loss. While the disorder is still considered rare, researchers emphasized the importance of awareness among physicians to educate patients about potential risks and to monitor for any warning signs.